EICHOR
● Active Not Recruiting
Atrasentan in Patients With IgA Nephropathy
Condition: IgA Nephropathy · Immunoglobulin A Nephropathy · Sponsor: Novartis Pharmaceuticals
About this study
The ALIGN Study is a phase 3, double-blind, placebo-controlled study to compare the efficacy and safety of atrasentan to placebo in patients with IgA nephropathy (IgAN) at risk of progressive loss of renal function.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (135)
| University of Alabama at Birmingham | Birmingham, Alabama, United States | — |
| Comprehensive Research Institute | Alhambra, California, United States | — |
| Kidney Disease Medical Group | Glendale, California, United States | — |
| Stanford University | Stanford, California, United States | — |
| University of Florida | Gainesville, Florida, United States | — |
| GA Nephrology Associates | Lawrenceville, Georgia, United States | — |
| NANI Research, LLC | Hinsdale, Illinois, United States | — |
| NANI Research, LLC | Fort Wayne, Indiana, United States | — |
| University of Louisville Physicians- Kidney Disease Program | Louisville, Kentucky, United States | — |
| Tufts Medical Center | Boston, Massachusetts, United States | — |
| Intermed Consultants | Minneapolis, Minnesota, United States | — |
| Pelican Point Dialysis - DaVita Clinical Research | Las Vegas, Nevada, United States | — |
+ 123 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04573478